Moderna says RSV vaccine 84% effective at preventing symptoms in older adults
Jan 17 (Reuters) - Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial in preventing at least two symptoms, such as cough and fever, in…